Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BPDO-1603 vs Separate Components in Healthy Adults
NCT05804279Phase 1Completed
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BPDO-1603 in Alzheimer's disease (AD) (2 arms), sponsored by Hyundai Pharmaceutical Co., Ltd. Primary endpoint: Maximum Plasma Concentration of Memantine and Donepezil at Day 10. Started Dec 2022; status: completed.
02
Drugs
BPDO-1603
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05804279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804279.